Multifield International Holdings Limited

Multifield International Holdings Limited

0898.HK
Multifield International Holdings LimitedHK flagHong Kong Stock Exchange
0.95
HKD
-0.02
- -
794.27MMarket Cap
Multifield International Holdings Limited
0898.HK
(Hong Kong Stock Exchange)

Recent

price

0.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.26
0.17
0.34
0.26
0.42
0.09
0.32
0.72
0.07
0.37
0.06
0.32
0.33
0.34
0.34
- -
Revenue per Share
0.61
0.21
0.64
0.85
0.57
0.79
0.62
0.78
0.88
0.64
0.01
0.5
0.32
0.21
0.28
- -
Basic EPS, GAAP
0.11
0.12
0.25
-0.43
0.24
-0.49
-0.02
0.36
0.26
0.5
0.04
0.23
0.18
0.21
-0.11
- -
Free Cash Flow per Basic Share
0.04
0.05
0.04
0.06
0.06
0.06
0.06
0.07
0.07
0.07
0.01
0.04
0.04
0.04
0.04
- -
Dividend per Share
0.08
0.08
3.23
4.06
4.96
5.34
5.98
6.69
7.5
8.06
1.59
8.44
8.71
8.88
9.12
- -
Book Value per Share
4.62
4.8
5.64
6.84
7.3
8.07
8.4
9.67
10.38
10.92
2.25
11.78
11.6
11.85
11.91
- -
Tangible Book Value per Share
836
836
836
836
836
836
836
836
836
836
4,180
836
836
836
836
- -
Basic Weighted Avg Shares
215
142
283
216
353
77
264
604
56
313
252
268
274
284
286
287
Sales/Revenue/Turnover
336.37
10.86
74.87
66.78
93.47
-2.21
66.35
83.29
-77.1
73.01
66.17
69.23
72.81
71.42
68.81
69.87
Operating Margin (%)
4
4
3
3
6
6
7
8
7
5
4
3
3
3
3
3
Depreciation Expense
512
172
536
710
480
660
516
651
733
531
37
421
264
179
235
-645
Net Income, GAAP
0.59
19.68
- -
8.26
7.47
29.29
22.3
1.31
11.71
- -
75.21
19.89
20.01
25.07
10.3
- -
Effective Tax Rate (%)
237.84
121.82
189.5
328.9
135.81
853.09
195.79
107.94
1,313.29
169.68
14.8
157.05
96.5
63.18
82.27
-224.71
Profit Margin (%)
-24
-433
-224
-220
-127
-253
-366
99
349
1,096
-62
24
59
638
1,683
2,146
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
385
1,110
400
- -
- -
660
1,393
1,320
LT Debt
3,859
4,009
4,718
5,723
6,101
6,749
7,022
8,088
8,680
9,132
9,419
9,853
9,696
9,904
9,958
9,481
Total Equity
16.05
0.26
- -
2.09
4.22
-0.02
1.53
5.15
-0.36
- -
0.37
1.3
1.4
1.33
1.52
- -
Return on Invested Capital (%)
37.3
8.73
- -
10.11
5.24
5.81
4.61
5.8
6.69
- -
0.72
3.52
1.79
1.59
2.32
- -
Return on Capital (%)
777.94
261.9
38.73
23.29
12.72
15.32
10.92
12.31
12.36
8.16
0.56
6.14
3.68
2.44
3.12
-8.85
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.58%
0.18%
-4.79%
Free Cash Flow
-294.22%
-86.72%
-282.56%
Net Income, GAAP
51.17%
123.07%
-374.25%
Sales/Revenue/Turnover
73.4%
2.62%
0.41%
Total Cash Common Dividend
- -
- -
-0.04%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
284
2024
- -
- -
- -
- -
286
2025
- -
- -
- -
- -
287

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.21
2024
- -
- -
- -
- -
0.28
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.04
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
- -
Business
Multifield International Holdings Limited engages primarily in the manufacturing and sale of pharmaceutical raw materials and intermediates, specialty chemicals, and biopharmaceutical ingredients. Its core product portfolio includes active pharmaceutical ingredients (APIs), pharmaceutical intermediates, chemical reagents, and related specialty chemical products catering to pharmaceutical companies, chemical manufacturers, and biotechnology firms. The company operates principally in Greater China and serves global markets through its extensive production and distribution network. Founded in 2003 and headquartered in Hong Kong, Multifield International Holdings Limited also explores business segments involving contract manufacturing services and research and development in chemical and pharmaceutical technologies. In terms of recent corporate developments, Multifield has focused on expanding its strategic partnerships and enhancing its production capabilities to meet evolving global pharmaceutical demands. Over the past 1-2 years, the company has pursued operational optimization and capacity expansion initiatives, supported by targeted acquisitions and collaborations within the pharmaceutical and specialty chemical industries, aiming to strengthen its integrated supply chain and innovation capacity. These moves align with Multifield's strategic direction to broaden its product offerings and geographic reach while reinforcing its position as a leading supplier of high-quality chemical and pharmaceutical raw materials in Asia and internationally. The company operates across multiple business segments including pharmaceutical intermediates, APIs, specialty chemicals, contract manufacturing, and chemical research and development. Its customer base spans pharmaceutical manufacturers, chemical suppliers, biotech firms, and healthcare product developers. Multifield’s growth strategy includes leveraging its research capabilities and production scale in Hong Kong and Mainland China to serve both domestic and export markets. The company is publicly listed on the Hong Kong Stock Exchange under the ticker 0898.HK and maintains several subsidiaries for operational and market-specific activities.